Prostvac

Nov 14, 2019

Trovagene Presents Positive Data in Metastatic Prostate Cancer Phase 2 Trial Showing Clinical Response in Patients Resistant to Zytiga®

Aug 15, 2019

Trovagene to Present New Data from Onvansertib Phase 2 Study in Metastatic Castration-Resistant Prostate Cancer at Asia-Pacific Prostate Cancer Conference

Apr 02, 2019

Early Data from Phase 2 Trial Indicates Activity of Onvansertib in Prostate Cancer Patients Showing Initial Resistance to Anti-Androgen Therapy

May 18, 2018

ERLEADA(TM) Significantly Reduced Risk of Prostate Specific Antigen (PSA) Progression in Patients with Non-Metastatic Castration-Resistant Prostate Cancer

Sep 06, 2017

Oxeia Biopharmaceuticals, Inc. Announces Appointment Of Dr. Michael Wyand As Chief Executive Officer

Jun 22, 2017

Prostate Specific Antigen Pipeline Therapeutics Development Review H1 2017 Says a New Research Report at RnRMarketResearch.com

Jun 03, 2017

ARMO BioSciences Announces Encouraging Survival Data Observed in Patients with Advanced Pancreatic Cancer in Phase 1/1b Trial of Immunotherapy AM0010